Development of a pseudo-typed virus particle based method to determine the efficacy of virucidal agents.

Publication date: Jan 25, 2024

The ongoing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic has highlighted the threat that viral outbreaks pose to global health. A key tool in the arsenal to prevent and control viral disease outbreaks is disinfection of equipment and surfaces with formulations that contain virucidal agents (VA). However, assessment of the efficacy of virus inactivation often requires live virus assays or surrogate viruses such as Modified Vaccinia Virus Ankara (MVA), which can be expensive, time consuming and technically challenging. Therefore, we have developed a pseudo-typed virus (PV) based approach to assess the inactivation of enveloped viruses with a fast and quantitative output that can be adapted to emerging viruses. Additionally, we have developed a method to completely remove the cytotoxicity of virucidal agents while retaining the required sensitivity to measure PV infectivity. Our results indicated that the removal of cytotoxicity was an essential step to accurately measure virus inactivation. Further, we demonstrated that there was no difference in susceptibility to virus inactivation between PVs that express the envelopes of HIV-1, SARS-CoV-2, and Influenza A/Indonesia. Therefore, we have developed an effective and safe alternative to live virus assays that enables the rapid assessment of virucidal activity for the development and optimization of virucidal reagents.

Open Access PDF

Concepts Keywords
Coronavirus Agents
Disinfection Assessment
Indonesia Based
Safe Cov
Vaccinia Developed


Type Source Name
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH viral disease
disease VO inactivation
disease VO Viruses
disease VO MVA
disease VO time
disease IDO infectivity
disease IDO susceptibility
pathway KEGG Influenza A
disease VO effective
drug DRUGBANK Coenzyme M
disease MESH infection
disease VO organ
disease MESH Middle East Respiratory Syndrome
disease IDO immunodeficiency
disease IDO replication
disease IDO host
disease IDO assay
drug DRUGBANK L-Glutamine
disease MESH Influenza
disease MESH AIDS
disease VO Tat
disease MESH shock
drug DRUGBANK Water
disease VO Glycoprotein
disease VO Gag
disease IDO production
disease VO Env
drug DRUGBANK Methylergometrine
disease VO syringe
disease IDO cell
drug DRUGBANK Ammonium chloride
drug DRUGBANK Ethanol
drug DRUGBANK Sulfate ion
disease VO storage
drug DRUGBANK Hyaluronic acid
disease MESH death
drug DRUGBANK Trestolone
disease IDO process
disease VO viability
drug DRUGBANK Ozone
disease MESH severe acute respiratory syndrome
disease MESH pneumonia
disease MESH etiology
disease MESH COVID 19
disease IDO intervention
disease VO effectiveness
drug DRUGBANK Povidone-iodine
disease MESH syndrome
disease VO organization
disease VO Vaccinia virus
disease VO protocol
disease VO efficient
disease VO Lentivirus

Original Article

(Visited 1 times, 1 visits today)